To understand osteoporosis, it is important to learn about bone. Made mostly of collagen, bone is living, growing tissue. Collagen is a protein that provides a soft framework, and calcium phosphate is a mineral that adds strength and hardens the framework. This combination of collagen and calcium makes bone strong and flexible enough to withstand stress. More than 99 percent of the body's calcium is contained in the bones and teeth. The remaining 1 percent is found in the blood.

Two types of bone are found in the bodycortical and trabecular. Cortical bone is dense and compact. It forms the outer layer of the bone. Trabecular bone makes up the inner layer of the bone and has a spongy, honeycomb-like structure.

Think of bone as a bank account where you deposit and withdraw bone tissue. During childhood and the teenage years, new bone is added to the skeleton faster than old bone is removed. As a result, bones become larger, heavier, and denser. For most people, bone formation continues at a faster pace than removal until bone mass peaks during the third decade of life.

After age 20, bone withdrawals can begin to exceed deposits. For many people, this bone loss can be prevented by continuing to get calcium, vitamin D, and exercise and by avoiding tobacco and excessive alcohol use. Osteoporosis develops when bone removal occurs too quickly, replacement occurs too slowly, or both. You are more likely to develop osteoporosis if you did not reach your maximum peak bone mass during your bone-building years.

Women are more likely than men to develop osteoporosis. This is because women generally have smaller, thinner bones than men have and because women can lose bone tissue rapidly in the first 4 to 8 years after menopause because of the sharp decline in production of the hormone estrogen. Produced by the ovaries, estrogen has been shown to have a protective effect on bone. Women usually go through menopause between age 45 and 55. After menopause, bone loss in women greatly exceeds that in men. However, by age 65, women and men tend to lose bone tissue at the same rate. Although men do not undergo the equivalent of menopause, production of the male hormone testosterone may decrease, and this can lead to increased bone loss and a greater risk of developing osteoporosis.

Osteoporosis is preventable for many people. Prevention is important because although there are treatments for osteoporosis, a cure has not yet been found. A comprehensive program that can help prevent osteoporosis includes:

The National Institutes of Health Osteoporosis and Related Bone Diseases ~National Resource Center acknowledges the assistance of theNational Osteoporosis Foundation in the preparation of this publication.

For updates and for any questions about any medications you are taking, please contact

U.S. Food and Drug AdministrationToll Free: 888-INFO-FDA (888-463-6332)Website: https://www.fda.gov

For additional information on specific medications, visit Drugs@FDA at https://www.accessdata.fda.gov/scripts/cder/daf. Drugs@FDA is a searchable catalog of FDA-approved drug products.

NIH Pub. No. 18-7876

See the original post:
What Is Bone? | NIH Osteoporosis and Related Bone Diseases National ...

often attributive

1

: one of the hard parts of the skeleton of a vertebrate

: any of various hard animal substances or structures (such as baleen or ivory) akin to or resembling bone

: the hard largely calcareous connective tissue of which the adult skeleton of most vertebrates is chiefly composed

2

3

bones plural

: the basic design or framework (as of a play or novel)

5

bones plural : thin bars of bone, ivory, or wood held in pairs between the fingers and used to produce musical rhythms

: a strip of material (such as whalebone or steel) used to stiffen a garment (such as a corset)

6

transitive verb

1

2

: to provide (a garment) with stays

3

: to rub (something, such as a boot or a baseball bat) with something hard (such as a piece of bone) in order to smooth the surface

4

US, vulgar slang : to have sexual intercourse with (someone)

Subscribe to America's largest dictionary and get thousands more definitions and advanced searchad free!

Here is the original post:
Bone Definition & Meaning - Merriam-Webster

What is bone?

Bone is living tissue that makes up the body's skeleton. There are 3 types of bone tissue, including the following:

Compact tissue. The harder, outer tissue of bones.

Cancellous tissue. The sponge-like tissue inside bones.

Subchondral tissue. The smooth tissue at the ends of bones, which is covered with another type of tissue called cartilage. Cartilage is the specialized, gristly connective tissue that is present in adults. It is also the tissue from which most bones develop in children.

The tough, thin outer membrane covering the bones iscalled theperiosteum. Beneath the hard outer shell of the periosteum are tunnels and canals through which blood and lymphatic vessels run to carry nourishment for the bone. Muscles, ligaments, and tendons may attach to the periosteum.

Bones are classified by their shapeas long, short, flat, and irregular. Primarily, they are referred to as long or short.

There are 206 bones in the human skeleton, not including teeth and sesamoid bones (small bones found within cartilage):

80 axial bones. This includes the head, facial, hyoid, auditory, trunk, ribs, and sternum.

126 appendicular bones. This includes arms, shoulders, wrists, hands, legs, hips, ankles, and feet.

Bone provides shape and support for the body, as well as protection for some organs. Bone also serves as a storage site for minerals and provides the mediummarrowfor the development and storage of blood cells.

The different types of bone cells include the following:

Osteoblast. Found within the bone, its function is to form new bone tissue.

Osteoclast. A very large cell formed in bone marrow, its function is to absorb and remove unwanted tissue.

Osteocyte. Found within the bone, its function is to help maintain bone as living tissue.

Hematopoietic. Found in bone marrow, its function is to produce red blood cells,white blood cells, and platelets.

Fat cells are also found within the bone marrow.

Because of the complexities of a bone's function, from providing strength and support for the body, to serving as a site for development and storage of blood cells, there are many disorders and diseases that can affect bone.

View post:
Anatomy of the Bone | Johns Hopkins Medicine

High protein intake from meat can lead to calcium loss and harm bone health

As to how consuming animal or plant protein impacts bone composition, many studies have been published. Numerous studies have shown that compared to plant-based protein, animal-based protein weakens bones. According to several research, persons who consume a lot of meat are more likely to develop osteoporosis (thin bone tissue) and fractures.

Resorption and formation of new bone are constantly balanced in healthy bones. Resorption is the breakdown of old bone to be reabsorbed (modeling). Most individuals are aware of the significance of calcium and vitamin D in the development and maintenance of strong bones. However, a theory that protein altered the body's natural chemistry in such a way that too much calcium was being excreted in urine emerged based on past research.

In one of her recent Instagram posts, nutritionist Anjali Mukerjee shares how meat protein can impact bone health. She writes, A high protein diet, especially from animal sources, can lead to calcium loss and harm bone health.

Meat has a high phosphorous-to-calcium ratio which increases calcium excretion and can cause bone demineralization.

Consuming animal protein, especially red meat, can make the blood acidic and lead to calcium being removed from bones.

She further writes, Protein is important for bone health, but too much animal protein, especially red meat, can actually harm your bones. So we need to make sure to include dairy, fish, chicken, and plant-based sources of protein in your diet, and don't forget to balance it with plenty of fruits, vegetables, and whole grains.

Look at her post:

Disclaimer: This content including advice provides generic information only. It is in no way a substitute for a qualified medical opinion. Always consult a specialist or your own doctor for more information. NDTV does not claim responsibility for this information.

Congress-Left Alliance 'Unholy', Joining BJP Like taking dip in Ganga: Tripura Chief Minister

Waiting for response to load...

The rest is here:
Bone Health: Is Eating Meat Healthy For Your Bones?

Where did my health go - A player after being grabbed once

Also known as The Boner, and the Bone OneBone KeeperSans hasn't been same after playing deepwoken...Health10000

(Regenerates 20 Health per second)

The Bone Keeper is a monster found in the Eternal Gale.

Bone Keepers are giant, humanoid creatures, with inhuman proportions, having extremely short legs and large arms. It has clearly clawed feet, with bone claws for hands. They sport a red & gold loincloth of sorts on their lower body and seemingly not having any clothes on their upper half. Their head also appears to be made out of bones or a bone-like material.

Bone Keepers are incredibly mobile and hard-hitting enemies. They are certainly a large difficulty step-up from the mobs found in Layer 1, however all of their attacks are well telegraphed and can be avoided with proper experience, though their damage yields greater punishment, were you to fail to avoid them.

Slash

Excerpt from:
Bone Keeper | Deepwoken Wiki | Fandom

AC Immune Partner Life Molecular Imaging Initiates Phase 3 Study of Tau PET Diagnostic PI-2620 for Alzheimer’s Disease

Here is the original post:
AC Immune Partner Life Molecular Imaging Initiates Phase 3 Study of Tau PET Diagnostic PI-2620 for Alzheimer’s Disease

The Company has already secured approvals from Ethics Committee and Israeli Ministry of Health for the Company's study with its proprietary SCI-210 treatment

See the original post here:
SciSparc Receives Approval to Conduct its Clinical Trial in Children with Autism Spectrum Disorder at the Soroka Medical Center

ROCKVILLE, Md., Jan. 18, 2023 (GLOBE NEWSWIRE) -- OpGen, Inc. (Nasdaq: OPGN, “OpGen” or “the Company”), a precision medicine company harnessing the power of molecular diagnostics and bioinformatics to help combat infectious disease, today announced preliminary unaudited revenue for 2022. Preliminary revenue for full year 2022 was approximately $2.7 million, which falls within the most recent guidance range the Company had provided in its Q3 earnings call. The year-end cash position as of December 31, 2022 amounted to approximately $7.4 million. On January 11, 2023, the Company successfully closed a public offering of securities raising gross proceeds of $7.5 million and net proceeds of approximately $6.8 million after deduction of placement agent commission and transaction related expenses.

Originally posted here:
OpGen Provides Preliminary Unaudited Revenue for FY 2022 and Business Update

Wound care professionals across multiple specialties to support strategic alignment of patient, payor, and provider goals Wound care professionals across multiple specialties to support strategic alignment of patient, payor, and provider goals

Read the original:
Arch Therapeutics Announces Formation of Medical Advisory Board to Advance Commercialization of AC5® Advanced Wound System

Global pivotal Phase 3 EFZO-FIT™ study in pulmonary sarcoidosis launched in Europe Global pivotal Phase 3 EFZO-FIT™ study in pulmonary sarcoidosis launched in Europe

Original post:
European Commission Grants Orphan Drug Designation for aTyr Pharma’s Efzofitimod for Treatment of Sarcoidosis

Barry Selick, Ph.D., successful biopharmaceutical scientist, senior executive and entrepreneur, appointed Chief Executive Officer

Original post:
Hinge Bio Expands Senior Management Team to Drive GEM-DIMER™ Programs to Clinical Development

Live video webcast on Thursday, January 19th at 12:00 PM ET Live video webcast on Thursday, January 19th at 12:00 PM ET

Originally posted here:
Novan to Present at the Virtual Investor 2023 Companies to Watch Event

MADRID, Spain and BOSTON, Jan. 18, 2023 (GLOBE NEWSWIRE) -- Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a clinical-stage biopharmaceutical company leveraging epigenetics to develop therapies in diseases with strong unmet medical need, announced today the enrollment of the first patient in a Phase II collaborative study with iadademstat in patients with relapsed/refractory high grade neuroendocrine carcinomas (NEC). This trial is conducted under a collaborative clinical research agreement entered between Oryzon and the Fox Chase Cancer Center (FCCC), under which FCCC will be conducting different collaborative combination clinical trials with iadademstat, with Oryzon providing funding, the drug and technical expertise.

View original post here:
ORYZON Announces First Patient In in NET, a Collaborative Phase II Basket Study With Iadademstat in R/R Patients With Neuroendocrine Carcinomas

TORONTO, Jan. 18, 2023 (GLOBE NEWSWIRE) -- PharmaTher Holdings Ltd. (the “Company” or “PharmaTher”) (OTCQB: PHRRF) (CSE: PHRM), a leader in specialty ketamine pharmaceuticals, is pleased to announce that it has applied with the U.S. Food and Drug Administration (“FDA”) to receive Orphan Drug Designation (“ODD”) for ketamine to treat Rett Syndrome, a rare genetic neurological disorder. Ketamine has been subject to a Phase 2 clinical trial (NCT03633058) for Rett syndrome. Unpublished results from this study will be evaluated to support a potential Phase 3 clinical study and FDA agreement on a regulatory plan for approval which the Company may pursue.

Continued here:
PharmaTher Holdings Submits for FDA Orphan Drug Designation for Ketamine to Treat Rett Syndrome

PORTLAND, Ore., Jan. 18, 2023 (GLOBE NEWSWIRE) -- Chalice Brands Ltd. (CSE: CHAL) (OTCQB: CHALF) (the “Company” or “Chalice Brands”), a premier consumer-driven cannabis company specializing in retail, production, processing, wholesale, and distribution, is pleased to announce that it has appointed Gary Zipfel to the Company’s Board of Directors (the “Board”), effective immediately.   The Company has also appointed William Simpson as an Advisor to the Board of Chalice Brands.

See the original post here:
Chalice Brands Announces New Appointment to Board of Directors

- Synergistic activity demonstrated with rencofilstat in combination with first line multiple myeloma drug, bortezomib -

See the article here:
Anti-Cancer Potential of Rencofilstat Expanded with Results from Preclinical Multiple Myeloma Studies

HONG KONG and SHANGHAI and FLORHAM PARK, N.J., Jan. 18, 2023 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM: HCM; HKEX:13) today announces, following negotiations with the China National Healthcare Security Administration (“NHSA”), ORPATHYS® (savolitinib) has been included in the updated National Reimbursement Drug List (“NRDL”) for the treatment of locally advanced or metastatic non-small cell lung cancer (“NSCLC”) adult patients with MET exon 14-skipping alterations who have progressed after or unable to tolerate platinum-based chemotherapy. The updated NRDL will take effect from March 1, 2023.

See original here:
HUTCHMED Announces Agreement with NHSA for Inclusion of ORPATHYS® in the National Reimbursement Drug List in China

Eascra to showcase Janus Base Nanomaterials (JBNs) in the Innovation category Eascra to showcase Janus Base Nanomaterials (JBNs) in the Innovation category

More here:
Eascra Biotech Selected as Finalist for 2023 SXSW Pitch

MARTINSRIED, Germany and MUNICH, Germany, Jan. 18, 2023 (GLOBE NEWSWIRE) -- Martinsried -- Medigene AG (Medigene, FSE: MDG1, Prime Standard), an immuno-oncology company focused on the development of differentiated, best-in-class T Cell Receptor engineered T cell (TCR-T) therapies, today announced that it has received a $3 million milestone payment from its partner 2seventy bio as part of its T cell receptor agreement in cancer immunotherapy, and which may lead to further potential milestone payments in the future. This payment follows the strategic alliance between 2seventy bio (Nasdaq: TSVT), and JW Therapeutics (HKEX: 2126), with the initial focus on the development of 2seventy bio’s MAGE-A4 program which employs a highly potent TCR discovered in collaboration with Medigene’s proprietary end-to-end technology platform.

See more here:
Medigene Receives $3 Million Milestone Payment from 2seventy bio

1 Growth at constant exchange rates and scope corresponds to organic growth of sales, excluding exchange rate variations, by calculating the indicator for the financial year in question and the indicator for the previous financial year on the basis of identical exchange rates (the exchange rate used is the previous financial year’s), and excluding change in scope, by calculating the indicator for the financial year in question on the basis of the scope of consolidation for the previous financial year.

Continued here:
VIRBAC: Annual revenue growth of +9.6% at comparable exchange rates and scope (+14.3% at real rates), driven by exceptional business activity in the...